June 20, 2025

Bilastine Key Quality API Parameters: Buyers Should Know

Bilastine API Parameters: Key Quality Standards Buyers Must Know

Introduction to Bilastine and API Quality Importance

In the evolving landscape of allergy treatment, bilastine has emerged as a second-generation antihistamine known for targeted symptom control in allergic rhinitis and urticaria. For pharmaceutical buyers and formulators, understanding bilastine API parameters is critical when evaluating suppliers and ensuring consistent product performance.

The effectiveness of any formulation depends heavily on the quality of its active pharmaceutical ingredients. This makes API selection a key decision point for procurement teams, contract manufacturing partners, and research-driven organizations. With over 80 years of pharmaceutical manufacturing heritage, BioSynth specializes in antihistamine APIs with a strong focus on quality, traceability, and regulatory compliance.

Understanding Bilastine API: Pharmacology and Composition

Bilastine is a non-sedating, selective histamine H1 receptor antagonist developed for oral administration. Compared to older antihistamines, it offers:

High receptor selectivity
Minimal central nervous system penetration
Predictable pharmacokinetic behavior

Because of these properties, the consistency of the bilastine API used during development and manufacturing becomes essential.

Why API Quality is Crucial for Bilastine-Based Formulations

The performance of the final drug product depends directly on defined quality parameters. Key considerations include:

Solubility and bioavailability: Particle size and micronization influence absorption
Impurity profile: Controlled levels ensure long-term safety
Polymorphic form: Impacts stability and dissolution
Residual solvents: Must comply with ICH Q3C guidelines

For Bilastine tablets, overly broad particle size distribution can affect blend segregation and compression uniformity during high-speed tablet manufacturing runs. Failure to meet these bilastine API parameters can lead to reduced efficacy, stability issues, and regulatory rejection.

BioSynth’s Commitment to High-Purity Bilastine API Manufacturing

At BioSynth, we make APIs with over 80 years of experience in pharmaceuticals. WHO-GMP and ISO 9001:2015 certify our facilities in Hyderabad. Our dedicated production lines follow robust Good Manufacturing Practices (GMP) to ensure each batch of bilastine API meets stringent pharmacopeial and client-specific requirements.

We leverage in-process analytical checks and validated stability protocols to ensure bilastine’s performance is consistent and compliant across geographies. At BioSynth, Bilastine production batches are monitored through validated in-process checkpoints covering moisture, particle size distribution (PSD), impurity trend lines, and final release specifications.

BioSynth follows quality, safety, documentation, and responsible manufacturing practices aligned with pharmaceutical compliance expectations. Our approach ensures that every batch of Bilastine API meets the highest standards globally.

Key Quality Bilastine API Parameters for Buyers

When sourcing from global API manufacturers like BioSynth, buyers should evaluate the following specifications:

Quality Parameter	Specification
Assay (%)	98.0%–102.0% (HPLC method)
Related Substances	Total ≤ 0.5%
Residual Solvents	As per ICH Q3C
Heavy Metals	As per ICH Q3D
Moisture Content	≤ 2.0% (Karl Fischer)
Chiral Purity	≥ 99%
Micronization (D90)	< 10 µm

Additional identifiers such as bilastine CAS number (202189-78-4) and product specifications should always be verified during procurement. This unique identifier ensures accurate identification across regulatory databases and maintains consistency in global supply chains.

Documentation and Regulatory Requirements

Reliable API suppliers in India provide complete regulatory support. Documentation packages are typically shared after commercial qualification or NDA-based evaluation depending on market and project scope. Key documents include:

Certificate of Analysis (COA)
Drug Master File (DMF)
Stability data (ICH compliant)
Impurity profile and safety data
Method validation reports
GMP compliance certificates

These documents are essential for pharmaceutical development and regulatory submissions worldwide.

How BioSynth Delivers Consistency Across Batches

Batch-to-batch consistency is often the Achilles’ heel of API manufacturing. At BioSynth, we use Process Analytical Technology (PAT) tools and a Quality by Design (QbD) approach. This ensures that every bilastine batch meets the required standards.

Our Compliance Framework:

ICH Q7 & Q3 Guidelines: Adherence from materials to finished API
Change Control System: Ensuring transparency and regulatory alignment for any process adjustments
Annual Product Reviews (APR): Comparative statistical analysis of batch trends
Trend Monitoring Tools: Using software-based control charts, outlier and drift detection for impurity levels and particle size distribution
Raw Material Traceability: Approved vendor controls, and batch genealogy records for uninterrupted regulated-market supply

Trend analysis across commercial batches helps identify early drift in assay, impurity levels, and particle size before impacting release timelines. This proactive approach minimizes regulatory delays and ensures supply continuity.

Choosing the Right API Manufacturer

Not all API manufacturers maintain the same standards. Many buyers face delayed launches due to incomplete documentation, inconsistent PSD, or changing impurity profiles from inexperienced suppliers. Buyers should assess:

GMP certifications (WHO-GMP, US FDA, EU-GMP)
Transparency in product documentation
Audit readiness and compliance history
Supply chain traceability
Technical team expertise and responsiveness

Buyers should compare multiple qualified suppliers based on compliance history, audit readiness, consistency, and documentation responsiveness. Lower-cost offers may appear attractive initially, but poor documentation or variability often increases long-term regulatory and production costs.

Working with experienced manufacturers like BioSynth reduces risks in both development and commercial supply. Our dedicated commercial and technical teams support qualification queries, specification alignment, and repeat-order planning.

Global Trends in API Procurement

API sourcing strategies are evolving. Key trends include:

Diversification of supply chains for risk mitigation
Growth in contract manufacturing partnerships (CDMO models)
Increased focus on traceability and compliance
Demand for environmentally responsible production

Procurement teams are prioritizing reliable suppliers with strong technical and regulatory capabilities. For example, CMOs supplying seasonal allergy products often prioritize dual sourcing with one documentation-ready Bilastine partner to reduce stockout risk and ensure uninterrupted supply during peak seasons.

Reference Standards Used

This article is informed by internationally recognized standards and regulatory guidelines:

ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
ICH Q3C: Residual Solvents Guideline
ICH Q3D: Elemental Impurities in Drug Products
Bilastine published clinical data and regulatory monographs
USP and Ph.Eur. Pharmacopeial Standards
WHO-GMP Guidelines for API Manufacturing

Scope and Disclaimer

This article is intended for procurement and technical guidance only. Final acceptance criteria may vary based on product dossier, market regulations, and customer specifications. Regulatory acceptance depends on country-specific requirements, dossier submissions, and health authority review. Supplier suitability should be independently assessed through audits, samples, and technical review.

Frequently Asked Questions

What assay is commonly expected for Bilastine API?

Typically 98.0%–102.0%, subject to agreed specifications. This range allows for normal analytical variation while ensuring product quality and regulatory compliance.

Can BioSynth support documentation for exports?

Qualified buyers may request COA, stability summaries, and regulatory support documents. Our team works with your regulatory requirements to provide necessary documentation for global market access.

What is the CAS Number for Bilastine API?

The CAS number is 202189-78-4. This globally recognized identifier ensures accurate identification of the substance across regulatory databases, manufacturing records, and scientific literature, maintaining consistency in global supply chains.

How does BioSynth ensure polymorph consistency?

Controlled crystallization protocols, detailed in validated SOPs, are combined with XRPD fingerprinting and DSC thermal analysis to confirm polymorphic form before batch release. Every batch CoA includes complete specifications.

What is the capacity of BioSynth for Bilastine API supply?

BioSynth can supply 2 MT/month of Bilastine API with the ability to customize as per customer requirements. We also offer bulk supply capabilities for large-scale pharmaceutical manufacturing.

Final Thoughts: Quality as a Competitive Advantage

The importance of bilastine API parameters extends beyond procurement. It directly impacts product quality, regulatory approval, and patient outcomes. Selecting the right API partner ensures consistency, compliance, and long-term reliability in pharmaceutical manufacturing.

For more information about Bilastine API sourcing, quality standards, and manufacturing capabilities, visit our BioSynth Bilastine API product page. You can also contact our team for detailed specifications and bulk order inquiries